Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Queensland Health
Covington
US Army
Dow
Johnson and Johnson
Merck
Moodys

Generated: October 18, 2018

DrugPatentWatch Database Preview

ALLERGAN Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?

ALLERGAN has one hundred and twenty-four approved drugs.

There are one hundred and seventy-seven US patents protecting ALLERGAN drugs.

Drugs and US Patents for ALLERGAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan PROPINE dipivefrin hydrochloride SOLUTION/DROPS;OPHTHALMIC 018239-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No 8,691,860 ➤ Try a Free Trial Y ➤ Try a Free Trial
Allergan Sales Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-003 Jul 18, 2016 RX Yes No 8,293,794 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ALLERGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 5,403,847 ➤ Try a Free Trial
Allergan ACULAR ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 019700-001 Nov 9, 1992 5,110,493*PED ➤ Try a Free Trial
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 6,620,435 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 2006-12-20
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 2008-08-19
➤ Subscribe Ophthalmic Solution 0.2%/0.5% ➤ Subscribe 2008-11-21
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 2014-10-29
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 2014-07-30
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 2011-04-05
➤ Subscribe Suppository 1000 mg ➤ Subscribe 2013-05-24
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2010-12-07
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2017-06-09
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 2017-07-25
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 2015-01-21
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 2009-03-02
➤ Subscribe Capsules 21 mg/10 mg ➤ Subscribe 2016-09-23
➤ Subscribe Ophthalmic Solution 0.40% ➤ Subscribe 2005-01-28
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 2016-08-30
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-24
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 2006-11-03
➤ Subscribe Gel 10% ➤ Subscribe 2014-06-19
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 2008-10-14
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 2008-12-22
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Ophthalmic Solution 0.30% ➤ Subscribe 2007-07-19
➤ Subscribe Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg ➤ Subscribe 2011-12-19
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 2010-05-03
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 2013-01-14
➤ Subscribe Capsules 14 mg/10 mg and 28 mg/10 mg ➤ Subscribe 2015-05-18
➤ Subscribe Gel 7.5% ➤ Subscribe 2017-02-13
➤ Subscribe Capsules 7 mg/10 mg ➤ Subscribe 2016-09-26
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-23
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 2014-08-12
Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Supplementary Protection Certificates for ALLERGAN Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90007-7 Sweden ➤ Try a Free Trial PRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE ENANTIOMER, DIASTEREOMER, RACEMATE OR SALT THEREOF; REG. NO/DATE: EU/1/16/1126 20160921
C/GB10/012 United Kingdom ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
/2017 Austria ➤ Try a Free Trial PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH ANNEHMBARES ENANTIOMER, DIASTEREOMER, RACEMAT ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 (MITTEILUNG) 20160921
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Moodys
Colorcon
US Army
UBS
Boehringer Ingelheim
Deloitte
Express Scripts
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.